Retrospective Analysis of Archived Pyrazinamide Resistant <i>Mycobacterium tuberculosis</i> Complex Isolates from Uganda—Evidence of Interspecies Transmission

Retrospective Analysis of Archived Pyrazinamide Resistant <i>Mycobacterium tuberculosis</i> Complex Isolates from Uganda—Evidence of Interspecies Transmission

The contribution of <i>Mycobacterium bovis</i> to the proportion of tuberculosis cases in humans is unknown. A retrospective study was undertaken on archived <i>Mycobacterium tuberculosis</i> complex (MTBC) isolates from a reference laboratory in Uganda to identify the preval...

Full description

Bibliographic Details
Main Authors:	Sylvia I. Wanzala, Jesca Nakavuma, Dominic Travis, Praiscillia Kia, Sam Ogwang, Wade Ray Waters, Tyler Thacker, Timothy Johnson, Syeda Anum Hadi, Srinand Sreevatsan
Format:	Article
Language:	English
Published:	MDPI AG 2019-07-01
Series:	Microorganisms
Subjects:	tuberculosis interspecies transmission whole genome sequencing SNPs zoonosis bovine TB pyrazinamide isoniazid
Online Access:	https://www.mdpi.com/2076-2607/7/8/221

Similar Items

New insights into the mechanism of action of pyrazinamide, implications for susceptibility testing, and future regimens*
by: Richard M Anthony, et al.
Published: (2016-01-01)

SIMULTANEOUS CONTENT ANALYSIS OF RIFAMPICIN, ISONIAZID, AND PYRAZINAMIDE IN TABLET DOSAGE FORM BY SPECTROPHOTOMETRY ULTRAVIOLET WITH DWM AND RSM
by: Muhammad Andry, et al.
Published: (2022-11-01)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in <it>Mycobacterium tuberculosis</it>
by: Parsons Linda M, et al.
Published: (2001-04-01)

Assessment of adherence to antituberculosis drug regimen among patients receiving isoniazid, rifampin and pyrazinamide: Kerman, Iran
by: Seyyed Mojtaba Sohrevardi, et al.
Published: (2019-07-01)

A Simple and Sensitive UPLC–UV Method for Simultaneous Determination of Isoniazid, Pyrazinamide, and Rifampicin in Human Plasma and Its Application in Therapeutic Drug Monitoring
by: Zhimei Jiang, et al.
Published: (2022-04-01)

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis
by: Mônica C. Façanha, et al.

An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage
by: Zhang-He Goh, et al.
Published: (2020-05-01)

Development of a HPLC Method for Analysis of a Combination of Clofazimine, Isoniazid, Pyrazinamide, and Rifampicin Incorporated into a Dermal Self-Double-Emulsifying Drug Delivery System
by: Daniélle van Staden, et al.
Published: (2023-11-01)

Drug rash with eosinophilia and systemic symptoms syndrome due to anti-TB medication
by: Dharmesh H Kaswala
Published: (2013-01-01)

A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period
by: Begum Lutfun Nahar, A.K.M. Mosharrof Hossain, M. Monirul Islam and Dipti Rani Saha
Published: (2006-12-01)

Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient
by: Angela Naomi Atomiya, et al.

Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient
by: Atomiya Angela Naomi, et al.
Published: (2002-01-01)

The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide
by: Géraldine Daneau, et al.
Published: (2016-01-01)

‘ZS-MDR-TB’ versus ‘ZR-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility
by: Ying Zhang, et al.
Published: (2012-07-01)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis [version 3; peer review: 1 approved, 2 approved with reservations]
by: Helen McIlleron, et al.
Published: (2024-03-01)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis [version 2; peer review: 1 approved, 2 approved with reservations]
by: Helen McIlleron, et al.
Published: (2022-11-01)

CNS tuberculoma in an immunocompetent patient: A case report of multi-drug hypersensitivity to RIPE therapy
by: Benjamin Huber, et al.
Published: (2023-01-01)

The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors
by: Kyle H. Rohde, et al.
Published: (2021-01-01)

New combination for patients with latent tuberculosis infection: A pilot study
by: Te-Yu Lin, et al.
Published: (2018-01-01)

Pyrazinamide-induced phototoxicity: A case report and review of literature
by: Katiyar Subodh, et al.
Published: (2010-01-01)

Influenza A virus infection of healthy piglets in an abattoir in Brazil: animal-human interface and risk for interspecies transmission
by: Ariane Ribeiro Amorim, et al.
Published: (2013-08-01)

Colorimetric methods for rapid determination of pyrazinamide resistance
by: Ahmet Ugur Akbal, et al.
Published: (2020-01-01)

Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine
by: Mohamed Abouzid, et al.
Published: (2024-01-01)

Is the Pharmacokinetics of First-Line Anti-TB Drugs a Cause of High Mortality Rates in TB Patients Admitted to the ICU? A Non-Compartmental Pharmacokinetic Analysis
by: Francisco Beraldi-Magalhaes, et al.
Published: (2023-06-01)

Correlations among the plasma concentrations of first-line anti-tuberculosis drugs and the physiological parameters influencing concentrations
by: Lin Cheng, et al.
Published: (2023-10-01)

Adverse Drug Reactions to a Daily Fixed-dose Combination Based Antituberculosis Treatment Regime in India’s National Tuberculosis Elimination Programme: A Prospective Cohort Study
by: Kapil Mate, et al.
Published: (2022-08-01)

Analysis of pncA gene expression in pyrazinamide-resistant and multidrug-resistant <i>Mycobacterium tuberculosis</i>
by: Wang Nan，, Yang Yu, Deng Ling, Wu Hui, Liu Zhihui, Meng Fanrong
Published: (2023-12-01)

Detection of pyrazinamide heteroresistance in Mycobacterium tuberculosis
by: Mikaela Glader, et al.
Published: (2015-01-01)

Pyrazinamide-induced maculopapular rash
by: Khayyam Khalid, et al.
Published: (2010-01-01)

Nigella sativa can Cure Hepatotoxicity Caused by Pyrazinamide Administration; A Lead from Animal Experiment
by: Amtul Hafeez, et al.
Published: (2020-12-01)

Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line
by: Nicolas de Oliveira Rossini, et al.
Published: (2023-01-01)

Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers
by: Naiyma Choudhary, et al.
Published: (2014-01-01)

In Situ Investigation of a Self-Accelerated Cocrystal Formation by Grinding Pyrazinamide with Oxalic Acid
by: Hannes Kulla, et al.
Published: (2016-07-01)

Clinical Significance of Preoperative Pyrazinamide-Containing Therapy in Tuberculous Constrictive Pericarditis
by: Fang L, et al.
Published: (2024-01-01)

Design, synthesis and biological activity of pyrazinamide derivatives for anti-Mycobacterium tuberculosis
by: Shiyang Zhou, et al.
Published: (2017-01-01)

Role of Nigella Sativa Seeds on Pyrazinamide Induced Hepatotoxicity
by: Amtul Hafeez , Akbar Waheed , Neelofar Yousaf
Published: (2019-03-01)

The protective effect of naringenin against pyrazinamide-induced hepatotoxicity in male Wistar rats
by: Atef Abdel-Moneem Ali, et al.
Published: (2022-10-01)

DEVELOPMENT OF DERIVATIVE SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS DETERMINATION OF PYRAZINAMIDE AND RIFAMPICIN IN CUBOSOME FORMULATION
by: Morgana Souza Marques, et al.
Published: (2021-06-01)

Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan
by: Hsin-Ting Huang, et al.
Published: (2023-12-01)

Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays
by: A. Bedini, et al.
Published: (2016-07-01)